A protein chimera self-assembling unit for drug delivery.

innovative biotechnologies personalized medicine targeted therapy virus-like particles

Journal

Biotechnology progress
ISSN: 1520-6033
Titre abrégé: Biotechnol Prog
Pays: United States
ID NLM: 8506292

Informations de publication

Date de publication:
03 2019
Historique:
received: 06 08 2018
revised: 15 11 2018
accepted: 05 12 2018
pubmed: 24 12 2018
medline: 14 3 2020
entrez: 22 12 2018
Statut: ppublish

Résumé

In the modern view of selective drug delivery of bioactive molecules, the attention is moving onto the setup of the perfect carrier more than in the optimization of the active compound. In this respect, virus-like particles constitute bioinspired nanodevices with the intrinsic ability to transport a large class of molecules, ranging from smart drugs to small interfering RNAs. In this work, we demonstrate the efficacy of a novel construct obtained by fusing a self-assembling protein from the human Rotavirus A, VP6, with the Small Ubiquitin Modifier domain, which maintains the ability to form nanoparticles and nanotubes and is able to be used as a drug carrier, even without specific targeting epitopes. The high expression and purification yield, combined with low toxicity of the empty particles, clearly indicate a good candidate for future studies of selective drug delivery. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 35: e2769, 2019.

Identifiants

pubmed: 30575331
doi: 10.1002/btpr.2769
doi:

Substances chimiques

Drug Carriers 0
Ubiquitin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2769

Informations de copyright

© 2018 American Institute of Chemical Engineers.

Auteurs

Adriana Amalfitano (A)

Istituto di Biochimica e Biochimica Clinica, Università Cattolica del Sacro Cuore, Rome, Italy.

Cecilia Martini (C)

Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy.

Giuseppina Nocca (G)

Istituto di Biochimica e Biochimica Clinica, Università Cattolica del Sacro Cuore, Rome, Italy.
Istituto di Chimica del Riconoscimento Molecolare, CNR, Rome, Italy.

Massimiliano Papi (M)

Istituto di Fisica, Università Cattolica del Sacro Cuore, Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.

Marco De Spirito (M)

Istituto di Fisica, Università Cattolica del Sacro Cuore, Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.

Maurizio Sanguinetti (M)

Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.

Alberto Vitali (A)

Istituto di Chimica del Riconoscimento Molecolare, CNR, Rome, Italy.

Francesca Bugli (F)

Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.

Alessandro Arcovito (A)

Istituto di Biochimica e Biochimica Clinica, Università Cattolica del Sacro Cuore, Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH